Role of adjuvant therapy in stage IIIC2 endometrial cancer

被引:10
|
作者
Bogani, Giorgio [1 ]
Cappuccio, Serena [2 ]
Casarin, Jvan [3 ]
Narasimhulu, Deepa Maheswari M. [4 ]
Cilby, William A. [4 ]
Glaser, Gretchen E. [4 ]
Weaver, Amy L. [5 ]
McGree, Michaela E. [5 ]
Keeney, Gary L. [6 ]
Weroha, John [7 ]
Petersen, Ivy A. [8 ]
Mariani, Andrea [4 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori Milano, Gynecol Oncol, Milan, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Dept Womans Childs & Publ Hlth, Rome, Italy
[3] Univ Insubria, Filippo Del Ponte Hosp, Dept Obstet & Gynecol, Varese, Italy
[4] Mayo Clin Rochester, Div Gynecol Oncol, Rochester, MN USA
[5] Mayo Clin Rochester, Div Biomed Stat & Informat, Rochester, MN USA
[6] Mayo Clin Rochester, Div Anat Pathol, Rochester, MN USA
[7] Mayo Clin Rochester, Div Med Oncol, Rochester, MN USA
[8] Mayo Clin Rochester, Dept Radiat Oncol, Rochester, MN USA
关键词
radiotherapy; LYMPH-NODE METASTASES; PARAAORTIC LYMPHADENECTOMY; RADIATION-THERAPY; SURVIVAL; DISSEMINATION; CHEMOTHERAPY; CARCINOMA; WOMEN; RISK; ADENOCARCINOMA;
D O I
10.1136/ijgc-2020-001446
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective The role of the different types of adjuvant treatments in endometrial cancer with para-aortic node metastases is unclear. The aim of this study was to report oncologic outcomes after adjuvant therapy in patients with stage IIIC2 endometrial cancer. Methods This retrospective single-institution study assessed patients with stage IIIC2 endometrial cancer who underwent primary surgery from January 1984 to December 2014. All patients had hysterectomy (+/- salpingo-oophorectomy) plus lymphadenectomy (para-aortic nodes, +/- pelvic nodes). We included all patients with stage III endometrial cancer and documented para-aortic lymph node metastases (International Federation of Obstetrics and Gynecologists stage IIIC2). We excluded patients who did not provide consent, who had synchronous cancer, or who underwent neoadjuvant chemotherapy. Follow-up was restricted to the first 5 years post-operatively. Cox proportional hazards models, with age as the time scale, was used to evaluate associations of risk factors with disease-free survival and overall survival. Results Among 105 patients with documented adjuvant therapy, external beam radiotherapy was administered to 25 patients (24%), chemotherapy to 24 (23%), and a combination (chemotherapy and external beam radiotherapy) to 56 (53%) patients. Most patients receiving chemotherapy and external beam radiotherapy (80%) had chemotherapy first. The majority of relapses had a distant component (31/46, 67%) and only one patient had an isolated para-aortic recurrence. Non-endometrioid subtypes had poorer disease-free survival (HR 2.57; 95% CI 1.38 to 4.78) and poorer overall survival (HR 2.00; 95% CI 1.09 to 3.65) compared with endometrioid. Among patients with endometrioid histology (n=60), chemotherapy and external beam radiotherapy improved disease-free survival (HR 0.22; 95% CI 0.07 to 0.71) and overall survival (HR 0.28; 95% CI 0.09 to 0.89) compared with chemotherapy or external beam radiotherapy alone. Combination therapy did not improve prognosis for patients with non-endometrioid histology (n=45). Conclusions In our cohort of patients with stage IIIC2 endometrioid endometrial cancer, those receiving chemotherapy and external beam radiotherapy had improved survival compared with patients receiving chemotherapy or external beam radiotherapy alone. However, the prognosis of patients with non-endometrioid endometrial cancer remained poor, regardless of the adjuvant therapy administered. Distant recurrences were the most common sites of failure.
引用
收藏
页码:1169 / 1176
页数:8
相关论文
共 50 条
  • [1] Chemoradiation Therapy Followed by Adjuvant Chemotherapy for Management of Stage IIIC2 Endometrial Cancer
    Klopp, A. H.
    Jhingran, A.
    Pardeshi, V.
    Schmeler, K.
    Bodurka, D.
    Lu, K.
    Eifel, P.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S191 - S191
  • [2] The role of adjuvant therapy in women with optimally cytoreduced stage IIIC endometrial cancer
    Alvarez-Secord, A.
    Watson, D.
    Holloway, R.
    Geller, M.
    Dao, N.
    Shular, K.
    Gehrig, P.
    O'Malley, D.
    Finkler, N.
    Havrilesky, L.
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S81 - S81
  • [3] Stage IIIC endometrial cancer review: Current controversies in adjuvant therapy
    Buras, Andrea L.
    Mallen, Adrianne
    Wenham, Robert
    Montejo, Michael
    [J]. GYNECOLOGIC ONCOLOGY REPORTS, 2021, 36
  • [4] Survival outcomes and patterns of failure in women with stage IIIC2 endometrial carcinoma
    Lee, Joon K.
    Mahan, Meredith
    Hanna, Rabbie K.
    Elshaikh, Mohamed A.
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2017, 216 : 192 - 197
  • [5] Recurrence patterns in patients with stage IIIC1 versus IIIC2 endometrial adenocarcinoma.
    Bevan, Catherine
    Nagel, Christa Irene
    Boren, Todd Patrtick
    Miller, David Scott
    Kehoe, Siobhan Marie
    Richardson, Debra L.
    Lea, Jayanthi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Stage IIIC1 versus IIIC2 endometrial adenocarcinoma of the uterus: Analysis of recurrence and patterns of toxicity
    Bevan, C.
    Nagel, C.
    Boren, T.
    Miller, D.
    Kehoe, S.
    Richardson, D.
    Albuquerque, K.
    Lea, J.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : S18 - S19
  • [7] A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer
    Secord, Angeles Alvarez
    Geller, Melissa A.
    Broadwater, Gloria
    Holloway, Robert
    Shuler, Kevin
    Dao, Nhu-y
    Gehrig, Paola A.
    O'Malley, David M.
    Finkler, Neil
    Havrilesky, Laura J.
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 128 (01) : 65 - 70
  • [8] Adjuvant treatment for stage IIIC endometrial cancer: Options and controversies
    Shah, Pratish H.
    Kudrimoti, Mahesh
    Feddock, Jonathan
    Randall, Marcus
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 122 (03) : 675 - 683
  • [9] IMPROVED DISEASE-FREE SURVIVAL WITH ADJUVANT RADIATION THERAPY (RT) IN PATIENTS WITH STAGE IIIC2 ENDOMETRIAL CARCINOMA - EXPERIENCE FROM TWO PROVINCES
    Stosky, Jordan
    Ko, Jenny
    Kumar, Aalok
    Tinker, Anna
    Holloway, Caroline
    Doll, Corinne
    Banerjee, Robyn
    Huang, Fleur
    Arora, Rahul
    Tien Phan
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S83 - S84
  • [10] Curative treatment for stage IIIC2 cervical cancer: what to expect?
    Mauro, Geovanne Pedro
    Calheiros, Vinicius de Aquino
    Vonsowski, Matheus Sorgi
    Avelar, Talita
    Carvalho, Heloisa de Andrade
    [J]. REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2023, 28 (03) : 332 - 339